Centennial, Colorado-based AlloSource has launched a novel allograft bone product within the AlloFuse family of demineralized bone grafts. The new bone allograft is comprised of Micro Fibers and is intended for use in spine, foot and ankle, and other orthopedic surgeries. The fibers, made entirely of demineralized cortical bone, do not require a separate carrier material.
AlloSource Adds Shorter DBM Fibers for Small Spaces
According to the processor, AlloSource, AlloFuse Micro Fibers Demineralized Bone allograft can be “formed into tightly compacted shapes to fill small boney voids and provides an osteoconductive scaffold with osteoinductive potential to support bone fusion. The short fiber size eliminates cutting or mincing, reducing unnecessary work, as well as time in the operating room and may be used in combination with biologics or autograft tissue as directed by the surgeon.”
Kevin Whitten, AlloSource chief commercial officer, explained to OTW the importance of the shorter bone fibers for surgery: “Surgeons wanted shorter fibers to fill small voids and spaces where bone fusion is needed. Collecting customer feedback on the initial product samples was an interesting part of our development process, and included a positive reaction to the Micro Fibers’ handling characteristics and ability to form them into tightly compacted shapes.”
Indeed, said Whitten, shorter demineralized bone fibers are actually an unmet need for surgeons and their patients. Finally, and importantly, noted Whitten, “Maximizing the gift of tissue donation, we developed Micro Fibers that are moldable and formable, allowing surgeons to maintain desired shapes, especially in small spaces.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.